Asthma drug shows promise in reducing lung blockages
NCT ID NCT05280418
First seen Jan 09, 2026 · Last updated May 14, 2026 · Updated 22 times
Summary
This study tested the drug tezepelumab in 27 adults with moderate-to-severe asthma that was not well controlled by current treatments. The goal was to see if the drug could improve how air moves through the lungs and reduce airway inflammation and mucus plugs. Participants received either tezepelumab or a placebo, and researchers used advanced imaging to measure changes over 16 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Firestone Institute for Respiratory Health
Hamilton, Ontario, L8N 4A6, Canada
Conditions
Explore the condition pages connected to this study.